A pivotal development for U.S. patients in 2026 is the Fourth Temporary Extension of telemedicine flexibilities regarding controlled substances. In early 2026, the Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) jointly announced that the ability for registered practitioners to prescribe Schedule II-V controlled substances via telemedicine has been extended through December 31, 2026. This "bridge" extension ensures that patients—including seniors, rural residents, and individuals with disabilities—can continue accessing care without interruption while permanent regulations are finalized.